A higher KI-67% is generally indicative of a faster-growing, potentially more aggressive tumor, which could influence treatment decisions, particularly regarding the use of adjuvant chemotherapy in hormone receptor-positive, HER2-negative breast cancer [50]. This evidence concerns the gene ERBB2 and breast carcinoma.